Baloxa 20 mg (Tablet)

Indications

• treatment of acute uncomplicated influenza
• patients 12 years of age and older
• symptomatic for no more than 48 hours
• otherwise healthy
• high risk of developing influenza-related complications
• post-exposure prophylaxis (PEP)
• following contact with an individual who has influenza

Pharmacology

• antiviral polymerase endonuclease inhibitor
• film-coated tablet for oral administration
• active component: Baloxavir Marboxil
• prodrug converted by hydrolysis to active form
• inhibition of influenza virus replication

Dosage & Administration

• single dose of Baloxavir orally
• within 48 hours of symptom onset
• dose based on weight
• 40 to less than 80 kg
• at least 80 kg
• Pediatric Use: for patients 12 years and older weighing at least 40 kg

Interaction

• avoid coadministration with dairy products
• avoid coadministration with calcium-fortified beverages
• avoid coadministration with polyvalent cation-containing laxatives
• avoid coadministration with antacids
• avoid coadministration with oral supplements
• live attenuated influenza vaccines may be affected

Contraindications

• hypersensitivity to Baloxavir Marboxil

Side Effects

• reporting 1% or more: diarrhea, bronchitis, nausea, sinusitis, headache

Pregnancy & Lactation

• no adequate and well-controlled studies in pregnant women
• risks to mother and fetus associated with influenza virus infection
• no data on presence in human milk, effects on breastfed infant, effects on milk production

Precautions & Warnings

• Hypersensitivity reactions
• Risk of bacterial infection

Overdose Effects

• general supportive measures
• monitoring of vital signs
• observation of clinical status
• no specific antidote

Therapeutic Class

• Respiratory viral infections (Influenza)

Storage Conditions

• Keep below 30°C
• Away from light & moisture
• Keep out of the reach of children

Related Brands

• Balovir 40 mg (Tablet) - acme-laboratories-ltd